Gastric cancer
Conditions
Interventions
the group of using Sintilimab for the first-line treatment:NA
the group of using Sintilimab for the second-line and above treatment:NA
Sponsors
Zhongda Hospital Affiliated to Southeast University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A. Patients who were diagnosed with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; B. Patients who plan to be treated with Sintilimab; C.ECOG score of 0-2; D. Expected survival >=3 months; E. The patient who have good compliance, follow-up, and can cooperate with relevant treatment and examination; F. Agree to participate in the study and sign the informed consent
Exclusion criteria
Exclusion criteria: A. Patients whose clinical information and data are incomplete; B. Patients who treated with immune checkpoint inhibitors within 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood concentration of Sintilimab; | — |
Secondary
| Measure | Time frame |
|---|---|
| the cytokines in peripheral blood:IL-1ß;the cytokines in peripheral blood:IL-2;the cytokines in peripheral blood:IL-4;the cytokines in peripheral blood:IL-6;the cytokines in peripheral blood:IL-8;the cytokines in peripheral blood:IL-10;the cytokines in peripheral blood:IFN-?;the cytokines in peripheral blood:TNF-a;the cytokines in peripheral blood:TNF-ß;inflammatory biomarkers in peripheral blood:NLR;inflammatory biomarkers in peripheral blood:PLR;inflammatory biomarkers in peripheral blood:LMR/MLR;inflammatory biomarkers in peripheral blood:LIPI;T lymphocyte subsets:CD4;T lymphocyte subsets:CD8;T lymphocyte subsets:Th1;T lymphocyte subsets:Th9;T lymphocyte subsets:Th17;fatty acid and bile acid metabolism:ursodeoxycholic acid;fatty acid and bile acid metabolism:short-chain fatty acid;fatty acid and bile acid metabolism:polyunsaturated fatty acids;anti-drug antibody; | — |
Countries
China
Contacts
Public ContactLin Liu
Zhongda Hospital Affiliated to Southeast University
Outcome results
None listed